OncoLink at ASCO 2000: Sunday, May 21

Due to severe weather causing flight delays, devoted OncoLink reporters Drs. Stripp and Levin drove from Philadelphia to New Orleans in order to provide coverage of ASCO 2000.

Pictured from left to right Dr. Diana Stripp, Dr. William Levin, Dr. Joel Goldwein, Founder of OncoLink, and Maggie Hampshire, RN, BSN, OCN, Managing Editor

3 Versus 6 Cycles of CMF in Breast Cancer Patients with 1 to 9 Positive Nodes: Results of the German Adjuvant Breast Cancer Group (GABG) III Trial Presenter: H. Maass Affiliation: GABC Background: For breast cancer, one of the standard adjuvant chemotherapy regimens is CMF for 6 cycles. Although there is clear data that prolonging CMF for more than 6 cycles is not beneficial, there are...
Comparative Cost-Effectiveness of Paclitaxel-Cisplatin (TP) vs Cyclophosphamide-Cisplatin (CP) in Women with Advanced Epithelial Ovarian Cancer: Results from a Randomized Trial Presenter: Hugh Walker Affiliation: Queens Univ. and Tom Baker Cancer Ctr, Canada Background: This sub-analysis of 160 patients in the intergroup trial (EORTC-GCCG, NOCOVA, NCIC-CTG, SGCSG) compares the cost effectiveness of paclitaxel (Taxol)...
Does pretreatment PSA add to predicting long-term survival from prostate cancer? Presenter: M. Roach III Affiliation: Univ of California San Francisco, Univ of Michigan Background: Numerous prognostic indicators, such as Gleason score and tumor stage are known to be significant in assessing risk of recurrence of or...
Induction Chemotherapy for High Grade Extremity Soft Tissue Sarcomas: Histologic Response and Correlation of Tumor Necrosis to Long Term Disease Free and Overall Patient Survival Presenter: R.M. Henshaw Affiliation: Washington Cancer Institute at Washington Hospital Center Background: The role of chemotherapy in soft tissue sarcoma remains controversial. Multiple randomized trials have shown no benefit in the...
Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results. Multicenter Phase II/III Study of Oxaliplatin Plus Cyclophosphamide (C) [OXC] Versus Cisplatin (P) Plus Cyclophosphamide [CPC] in Advanced Chemonaive Ovarian Cancer (AOC) Patients (Pts): Final Results (Abstract 1502) Presenter: Jean Louis Misset Affiliation: Htpital Paul Brousse, Villejuif, France; Ctr Oscar Lambret, Lille, France; Ctr Jean Perrin, Clermont-Ferrand, France; Inst Curie, Paris, France; Ctr Hospitalier, Bourg en Bresse, France; Clin St Pierre,...
The Role of Radiotherpay and Tamoxifen in the Management of Node Negative Invasive Breast Cancer </= 1.0 cm Treated with Lumpectomy: Preliminary Results of NSABP Protocol B-21 Presenter: N. Wolmark Affiliation: NSABP Background: Although definitive radiation therapy after lumpectomy has been standard of care for breast conservation for breast cancer, there has been some debate if radiation therapy is needed for ...